Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
5.48 ^USD	-1.79%		+8.73%	+29.86%

05-15	Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results	MT
05-15	Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness	CI

Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2022

August 03, 2022 at 04:12 pm

Vanda Pharmaceuticals Inc. Provided Revenue Guidance for the full year 2022. For the year, the company expects total revenues to be in the range of $240 million to $280 million.

Latest news about Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Says Second Phase 3 Study of Tradipitant in Motion Sickness Yields 'Positive' Results	05-15	MT
Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness	05-15	CI
Transcript : Vanda Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M	05-08	MT
Vanda Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	05-07	MT
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	05-07	MT
Sector Update: Health Care	05-07	MT
Vanda Pharmaceuticals Shares Rise After Future Pak Adds $260 Million Potential Payments to Cash Offer	05-07	MT
Future Pak sweetens buyout offer for Vanda Pharmaceuticals	05-07	RE
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer	04-25	RE
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	04-22	MT
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents	04-22	RE
Butler Hall Capital urges Vanda to engage in sales discussions	04-19	RE
Deals of the day-Mergers and acquisitions	04-17	RE
Sector Update: Health Care Stocks Retreating Late Afternoon	04-17	MT
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	04-17	MT
Sector Update: Health Care	04-17	MT
Top Midday Gainers	04-17	MT
Vanda Pharmaceuticals Adopts Stockholder Rights Plan; Shares Rise	04-17	MT
Vanda Pharmaceuticals' Board Rejects all Unsolicited Takeover Proposals From Future Pak	04-17	MT
Vanda Pharmaceuticals rejects takeover proposal from Future Pak	04-17	RE
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	04-17	MT
Top Premarket Gainers	04-17	MT
Vanda Pharmaceuticals Gets Acquisition Proposal From Future Pak; Shares Rise Pre-Bell	04-17	MT

Chart Vanda Pharmaceuticals Inc.

Duration

Period

More charts

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Vanda Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.48 USD

Average target price

5.21 USD

Spread / Average Target

-4.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VANDA PHARMACEUTICALS INC.	+29.86%	319M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs